News >

Transformative Agents Push Progress in HER2+ Breast Cancer

Caroline Seymour
Published: Friday, Aug 09, 2019

Tessa Cigler, MD, MPH, an associate professor of clinical medicine at Weill Cornell Medical College and an associate attending physician at NewYork-Presbyterian Hospital

Tessa Cigler, MD, MPH

The emergence of HER2-targeted therapies has transformed the prognosis of HER2-positive breast cancer, and each successive therapy continues to further the progress, explained Tessa Cigler, MD, MPH, in a presentation during the 2019 OncLive® State of the Science Summit on Breast Cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x